- [6] P. Gouzerh, A. Proust, Chem. Rev. 1998, 98, 77 112, and references therein
- [7] a) Q. Chen, D. P. Goshorn, C. P. Scholes, X. Tan, J. Zubieta, J. Am. Chem. Soc. 1992, 114, 4667–4681; b) A. Müller, J. Meyer, H. Bögge, A. Stammler, A. Botar, Z. Anorg. Allg. Chem. 1995, 621, 1818–1831.
- [8] H. K. Chae, W. G. Klemperer, V. W. Day, Inorg. Chem. 1989, 28, 1423-1424.
- [9] a) A. Messerschmidt, L. Prade, R. Wever, *Biol. Chem.* 1997, 378, 309 315; b) M. Weyand, H.-J. Hecht, M. Kieß, M.-F. Liaud, H. Vilter, D. Schomburg, *J. Mol. Biol.* 1999, 293, 595 611.
- [10] Crystal-structure analysis for 1: Single-crystal X-ray diffraction data were collected on a Bruker Nonius Smart diffractometer with a CCD detector ($\lambda(Cu_{K\alpha}) = 1.54184$ Å) at 200(2) K, crystal dimensions $0.16 \times$ 0.12 × 0.06 mm³. Structure solution was achieved by applying direct statistical methods of phase determination using the SHELXS program, and full-matrix least-squares refinements were performed using the SHELXL-97 software: Monoclinic, space group $P2_1/c$, a =15.132(3), b = 15.934(3), c = 13.290(3) Å, $\beta = 98.78(3)^{\circ}$, V = 15.132(3)3166.8(11) ų, $\rho_{\rm calcd} = 1.708~{\rm g\,cm^{-3}},~2\theta_{\rm max} = 51.9^{\circ},~{\rm total~collected~re}$ flections 18280, unique reflections 5858, $R_{int} = 0.0786$, $\mu = 1.218 \text{ mm}^{-1}$, $R_1 = 0.0597$ and $wR_2 = 0.1539$ for $I > 2\sigma(I)$, $R_1 = 0.0878$ and $wR_2 =$ 0.1627 for all reflections, 425 total parameters, GooF = 0.967 on $|F^2|$, max./min. residual electron density 1.131/-0.555 e Å⁻³. CCDC-176210 (1) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc. cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.ac.uk).
- [11] N. E. Brese, M. O'Keeffe, *Acta Crystallogr. Sect. B* **1991**, 47, 192–197. The oxidation state of atom i is given by $\Sigma_j \nu_{ij} = V$ with $\nu_{ij} = \exp[(R_{ij} d_{ij})/b]$. Here b is taken to be a "universal" constant equal to 0.37 Å, ν_{ij} is the valence of a bond between two atoms i and j, R_{ij} is given by the empirical parameters, and d_{ij} is the observed length of the bond.

Benzylic *endo*-Alkylation of Phthalan – Cr(CO)₃ Complexes via Temporary Silylation: An Entry to *trans*-1,3-Disubstituted Dihydroisobenzofurans**


Saskia Zemolka, Johann Lex, and Hans-Günther Schmalz*

Substituted 1,3-dihydroisobenzofurans (phthalans) represent an interesting class of compounds owing to their promising pharmacological potential,^[1] but they have received only little attention from synthetic chemists in the past.^[2] In particular, almost no general methods are available for the stereoselective synthesis of *cis*- or *trans*-1,3-disubsti-


[*] Prof. Dr. H.-G. Schmalz, S. Zemolka, Dr. J. Lex^[+] Institut für Organische Chemie, Universität zu Köln Greinstrasse 4, 50939 (Germany) Fax: (+49)221-470-3064 E-mail: schmalz@uni-koeln.de

- [**] This work was supported by Aventis Pharma Deutschland GmbH and the Fonds der Chemischen Industrie. The authors thank Dr. H. Schmickler and Dr. M. Schäfer for their invaluable support with advanced NMR spectroscopic and MS spectrometric techniques. Gifts of chemicals from Aventis and Chemetall AG are gratefully acknowledged.
- [+] X-ray crystallographic analysis.
- Supporting information for this article is available on the WWW under http://www.angewandte.com or from the author.

tuted derivatives of type **1** and **2**, respectively. [3] With regard to the usefulness of such compounds as intermediates for the synthesis of bioactive oxonanes [4] and the established biological activity of compounds of type **3**, [5] the search for efficient stereoselective entries to 1,3-disubstituted phthalans remains a challenging task.



In 1989, Davies and co-workers reported the preparation of a few *cis*-configured compounds of type **1** (R¹, R² = Me, D) starting from the [phthalan – Cr(CO)₃] complex **4**.^[6] In two successive benzylic deprotonation/alkylation steps, **4** can be transformed (via *rac*-**5**) into bis-*exo*-alkylated complexes of type **6**, from which the free ligands **1** are easily obtained by oxidative decomplexation.^[6] The method exploits both the ability of the Cr(CO)₃ fragment to stabilize a negative charge in the benzylic position^[7] and the strong steric effect of the metal fragment (shielding of the *endo* face).^[7b, 8] The stabilization of the anionic intermediate **7a** derived from **4** by benzylic deprotonation can be understood in terms of the resonance structure **7b** in which the charge is delocalized to the Cr(CO)₃ unit (Scheme 1).^[9]



Scheme 1. Resonance structures of the benzylic anion derived from 4.

In the course of our research on the application of chiral arene – Cr(CO)₃ complexes in the stereoselective synthesis of bioactive compounds,^[10] we were interested in using the silylated complex **8** as a building block for the synthesis of new 1,3-disubstituted phthalans. Compound **8** was selected since it is easily prepared, even in the optically active form,^[11] from the parent complex **4**. Herein we disclose the results of a study which has led to the discovery of some unexpected, remarkably selective transformations and to the development of an efficient and completely stereoselective route to 1-endoalkylated complexes and to *trans*-1,3-disubstituted phthalans.


When complex rac-8 was treated with tBuLi at low temperatures (-100 to -78°C) followed by quenching of the resulting anion with different electrophiles, we were surprised to find that the 1,1-disubstituted products (rac-11) were formed with complete regio- and diastereoselectivity (Table 1). Evidently, the deprotonation of rac-8 does not, as

Table 1. Preparation of 1,1-disubstituted complexes of type $\it rac$ -11 according to Scheme 2.

Starting material	Electrophile (R¹X)	Method ^[a]	Product	\mathbb{R}^1	Yield [%] ^[b]
rac-8	MeI	A	rac- 11 a	Me	76
rac-8	allyl bromide	A	rac-11 b	allyl	80
rac-8	nBuI	A	rac-11 c	nBu	83
rac-8	TMSCl	A	rac-11 d	TMS	72
rac-8	$TBSOC_5H_{10}I$	A	rac-11 e	$TBSOC_5H_{10}$	54
rac-8	BnOCOCl	A	rac-11 f	CO_2Bn	57
4	MeI	В	rac-11 a	Me	96
4	allyl bromide	В	rac-11 b	allyl	99
4	nBuI	В	rac-11 c	nBu	78
4	H_2O	В	rac-11 g	H	96
4	MeOD	В	rac- 11 h	D	83

[a] Method A: rac-8, THF, tBuLi (1.1 equiv), $-100 \rightarrow -78^{\circ}C$, 1 h, then R¹X (2.5-5 equiv), $-78 \rightarrow -45^{\circ}C$, 1-5 h (TLC control), then H₂O quench and extractive workup; method B: 4, THF, TMSCl (1.01 equiv), $-100^{\circ}C$, then tBuLi (2.2 equiv), 2 h, $-100 \rightarrow -78^{\circ}C$, then tBuLi (3 equiv), $-78 \rightarrow -50^{\circ}C$, 1-3.5 h (TLC control). [b] Yield of isolated product after

originally anticipated (see below), lead to the intermediate *rac-9a* (Scheme 2). Instead, the isomeric benzylic anion *rac-9b* is generated, which is subsequently alkylated by the



Scheme 2. Unexpected formation of 1,1-disubstituted complexes of type 11 by deprotonation/alkylation of 8. For details see Table 1.

electrophile (R¹X) from the unhindered *exo* face. Thus, the bulky TMS group ends up in the *endo* position with respect to the $Cr(CO)_3$ fragment, as found in the X-ray crystal structures of **11 a** and *rac-***11 d** (Figure 1).^[12]

Starting from **4**, the preparation of 1,1-disubstituted complexes of type *rac-***11** could also be carried out in an efficient one-pot procedure (Scheme 2): treatment of a solution of **4**




Figure 1. Structure of 11a (left) and rac-11d (right) in the crystalline ctota [12]

and TMSCl (1 equiv) in THF with tBuLi (2 equiv) at low temperatures (-100 to $-78\,^{\circ}C$) under in situ quench (ISQ) conditions^[11, 13] directly afforded a deep red solution of the benzylic anion (rac-**9b**), which could be quenched (as before) with different electrophiles to give the products usually even in better yields than in the former two-step procedure (Table 1).

The clean access to compounds of type **11** opened interesting perspectives for further transformations (see below). However, we were puzzled by the fact that deprotonation of **8** with tBuLi selectively affords the intermediate **9b**, even at $-100\,^{\circ}$ C (i.e. kinetic control). We had expected the isomeric species **9a** to be formed, anticipating the benzylic deprotonation of **8** to occur from the *exo* face. [14] Clearly, **9b** is thermodynamically more stable than **9a** as a result of the α -silyl effect. [15] The question was whether an *endo* deprotonation had occurred at the highly hindered silylated position of **8**

(H_{endo} at C1) or if **9b** was possibly formed by rearrangement of **9a** generated by a "standard" *exo* deprotonation at the unhindered opposite benzylic position (H_{exo} at C3) (Schemes 2 and 3).

To distinguish between these two possibilities, we decided to employ the deuterated derivative *rac-***13** (*rac-*[D₁]**8**) in a deprotona-

Scheme 3. Deprotonation (3-exo versus 1-endo) of complex **8**.

tion/alkylation sequence. Compound rac-13 was prepared by diastereoselective complexation ([Cr(CO)₆], nBu_2O/THF , reflux) of rac-12, [16] which in turn was obtained from rac-11h by oxidative decomplexation. When rac-13 was deprotonated with tBuLi at -78 °C and the resulting anion was quenched with allyl bromide, the completely dedeuterated product rac-11b was isolated in 69% yield (Scheme 4).[17] This result clearly demonstrates that, in contrast to established arene – Cr(CO)₃ chemistry,

Scheme 4. Proof of the 1-*endo*-deprotonation of **8** by using the deuterated derivative **13**. The experiment was carried out with the racemic compounds. Reagents and conditions: step 1: $[Cr(CO)_6]$ (1.08 equiv), nBu_2O/THF (10:1), 155 °C, 27 h; step 2: tBuLi (1.1 equiv), THF, -78 °C, 2 h, then allyl bromide (2 equiv), 2 h.

the deprotonation of *rac-8* indeed proceeds from the *endo* face (at the silylated position). Most likely, the enhanced acidity at C1 as a result of the TMS substituent overcompensates the shielding of the *endo* face by the Cr(CO)₃ fragment in this specific case (Scheme 3).^[18]

Desilylation of compounds of type *rac-***11** with tetrabutylammonium fluoride (TBAF) in the presence of water furnished the monosubstituted complexes *rac-***15** as pure *endo*

diastereomers in excellent yields through diastereoselective protonation of the intermediate anion *rac-***14** from the *exo* face (Scheme 5).^[19]

TBAF

$$Cr(CO)_3$$
 R¹

TMS

 $Cr(CO)_3$ R¹
 $Cr(CO)_3$ R¹
 $Cr(CO)_3$ R¹
 $Cr(CO)_3$ H

15a: R¹ = Me (96%)
15b: R¹ = allyl (87%)
15c: R¹ = r Bu (91%)

Scheme 5. Desilylation of complexes of type 11 leads to *endo-*alkylated products of type 15 through *exo* protonation of the intermediate 14. Reagents and conditions: THF, $\rm H_2O$, $\rm 0^{\circ}C$, TBAF (3 equiv), 10 min, room temperature, 12 h.

The newly developed, unique entry to *endo*-alkylated products prompted us to investigate the possibility of utilizing the silylated complexes *rac-11* in the synthesis of *trans-1,3*-disubstituted phthalans. Indeed, after subjecting complexes of type *rac-11* to the typical deprotonation/alkylation conditions and direct desilylation of the intermediates *rac-16*, the *trans-1,3*-disubstituted complexes *rac-17* were obtained as pure diastereomers (Scheme 6, Table 2). The expected *trans* con-

Scheme 6. One-pot synthesis of *trans*-1,3-disubstituted phthalan complexes of type **17**. For details, see Table 2.

Table 2. Preparation of trans-1,3-disubstituted complexes of type rac-17 according to Scheme 6.[a]

Starting material	Electrophile (R ² -X)	Product	\mathbb{R}^1	\mathbb{R}^2	Yield [%] ^[b]
rac- 11 a	allyl bromide	rac- 17 a	Me	allyl	91
rac- 11 a	nBuI	rac- 17b	Me	nBu	76
rac- 11 a	BnBr	rac- 17 c	Me	Bn	72
rac- 11 a	MeSSMe	rac-17 d	Me	S-Me	67
rac- 11 a	Et2NCOCl	rac- 17 e	Me	CONEt ₂	56
rac- 11 a	EtOCOCl	rac-17 f	Me	CO ₂ Et	56 ^[c]
rac- 11 b	nBuI	rac- 17 g	allyl	nBu	50
rac- 11 b	MeI	rac-17 h	allyl	Me	77
rac-11 c	BnBr	rac- 17 i	nBu	Bn	77

[a] THF, tBuLi (1.1 equiv), $-78\,^{\circ}$ C, 2 h, then R^2 X (2–4 equiv), $-78 \rightarrow -10\,^{\circ}$ C, 1 to 5 h (TLC control), then H_2 O, room temperature, $0\,^{\circ}$ C, then TBAF (1.5–7.5 equiv), room temperature, 12 h; extractive workup. [b] Yield of isolated product after chromatographic purification. [c] Inverse addition: the anion was added at $-78\,^{\circ}$ C to R^2 X in THF, then 2 h, $-78\,^{\circ}$ C.

figuration of the products was unequivocally proven by means of X-ray crystallographic analysis in the cases of *rac-***17 b** and *rac-***17 f** (Figure 2)^[12] and NMR spectroscopic correlations.

To demonstrate the applicability of the developed methodology in the preparation of nonracemic compounds, the chirogenic step (i.e. the deprotonation of the prochiral complex 4) was performed enantioselectively^[11] by using the




Figure 2. Structure of rac-17b (left) and rac-17f (right) in the crystalline state. [12]

chiral amide base 18.^[20] Therefore, 4 was treated with 18 (1 equiv) in the presence of TMSCl (ISQ conditions) at $-100\,^{\circ}$ C, and the intermediate 8 (formed in situ) was directly converted by deprotonation with tBuLi and an electrophilic quench (MeI) into complex $11\,a^{[12]}$ with >99% ee (HPLC) in 75% yield (Scheme 7, Figure 1).^[21] By combining the transformations shown in Scheme 7 ($4\rightarrow 11$) and Scheme 6 ($11\rightarrow 17$) the diastereo- and enantioselective synthesis of trans-1,3-disubstituted phthalan complexes can be carried out through a short and efficient sequence of two one-pot procedures.

Scheme 7. One-pot, enantioselective synthesis of **11a**. Reagents and conditions: TMSCl (1.01 equiv), **18** (1.08 equiv), THF, $-100\,^{\circ}$ C, then slow addition of **4** in THF, $-95 \rightarrow -85\,^{\circ}$ C, 45 min., then *t*BuLi (2.3 equiv), $-78\,^{\circ}$ C, 1 h, MeI (5 equiv), 1 h.

In conclusion, we have succeeded in elaborating a general, practical, and fully stereoselective entry to *trans*-1,3-dialky-lated dihydroisobenzofurans. The method exploits the remarkable and unexpected finding that the deprotonation of **8** occurs at the substituted benzylic position (from the *endo* face!). Our current investigations are aimed at the application of this method to the synthesis of more sophisticated systems related to bioactive natural products.

Received: February 7, 2002 [Z18667]

a) A prominent example of a bioactive phthalan is the antidepressant citalopram; see: B. G. Pollock, *Expert Opin. Pharmacother.* 2001, 2, 681; b) R. G. Lovey, A. J. Elliott, J. J. Kaminski, D. Loebenberg, R. M. Parmegiani, D. F. Rane, V. M. Girijavallabhan, R. E. Pike, H. Guzik, B. Antonacci, T. Y. Tomaine, *J. Med. Chem.* 1992, 35, 4221.

^[2] a) W. Friedrichsen in Advances in Heterocyclic Chemistry, Vol. 37 (Ed.: A. R. Katritzky), Academic Press, London, 1999, p. 1; b) B. A. Keay, P. W. Dibble in Comprehensive Heterocyclic Chemistry II, Vol. 2 (Eds.: A. R. Katritzky, C. W. Rees, E. F. V. Scriven), Pergamon, London, 1996, p. 395.

^[3] a) D. F. Ewing, C. Len, G. Mackenzie, G. Ronco, P. Villa, *Tetrahedron: Asymmetry* 2000, 11, 4995; b) D. F. Ewing, N.-E. Fahmi, C. Len, G.

- Mackenzie, A. Pranzo, *J. Chem. Soc. Perkin Trans.* 1 2000, 3561; c) B. Chao, D. C. Dittmer, *Tetrahedron Lett.* 2000, 41, 6001.
- [4] a) M. C. Elliott, C. J. Moody, T. J. Mowlem, Synlett 1993, 909; b) D. S.
 Brown, M. C. Elliott, C. J. Moody, T. J. Mowlem, J. Chem. Soc. Perkin Trans. 1 1995, 1137.
- [5] For antisecretory and antihistamine activities, see: a) S. Ram, A. K. Saxena, P. C. Jain, G. K. Patnaik *Indian J. Chem. Sect. B* 1984, 23, 1261;
 b) M. W. Klohs, F. J. Petracek (Dart Industries Inc.), US Patent 3471519, 1969 [Chem. Abstr. 1969, 71, 124212].
- [6] S. J. Coote, S. G. Davies, D. Middlemiss, A. Naylor, J. Organomet. Chem. 1989, 379, 81.
- [7] For reviews, see: a) S. G. Davies, S. J. Coote, C. L. Goodfellow in Advances in Metal-Organic Chemistry, Vol. 2 (Ed.: L. S. Liebeskind), JAI, London, 1989, p. 1; b) S. G. Davies, T. D. McCarthy in Comprehensive Organometallic Chemistry II, Vol. 12 (Eds.: E. W. Abel, F. G. A. Stone, G. Wilkinson), Pergamon, New York, 1995, p. 979.
- [8] a) H.-G. Schmalz, S. Siegel in *Transition Metals for Organic Synthesis*, Vol. 1 (Eds.: M. Beller, C. Bolm), Wiley-VCH, Weinheim, 1998, p. 550; b) M. Uemura in *Advances in Metal-Organic Chemistry*, Vol. 2 (Ed.: L. S. Liebeskind), JAI, London, 1989, p. 195.
- [9] a) A. Pfletschinger, T. K. Dargel, H.-G. Schmalz, W. Koch, *Chem. Eur. J.* 1999, 5, 537; b) C. A. Merlic, J. C. Walsh, D. J. Tantillo, K. N. Houk, *J. Am. Chem. Soc.* 1999, 121, 3596.
- [10] For selected recent work, see: a) F. Dehmel, H.-G. Schmalz, Org. Lett. 2001, 3, 3579; b) D. Hörstermann, H.-G. Schmalz, G. Kociok-Köhn, Tetrahedron 1999, 55, 6905; c) T. Geller, H.-G. Schmalz, J. W. Bats, Tetrahedron Lett. 1998, 39, 1537; d) K. Schellhaas, H.-G. Schmalz, J. W. Bats, Chem. Eur. J. 1998, 4, 57; e) H.-G. Schmalz, A. Majdalani, Synlett 1997, 1303
- [11] a) R. A. Ewin, N. S. Simpkins, Synlett 1996, 317; b) R. A. Ewin, A. M. MacLeod, D. A. Price, N. S. Simpkins, A. P. Watt, J. Chem. Soc. Perkin Trans. 1 1997, 401; for a review, see: c) S. E. Gibson (née Thomas), E. G. Reddington, Chem. Commun. 2000, 989.
- [12] For details of the crystal structure analyses of compounds *rac-11d*, 11a, *rac-17b*, and *rac-17f*, see Supporting Information. CCDC-179013 (*rac-11d*), CCDC-179014 (11a), CCDC-179015 (*rac-17b*), and CCDC-179016 (*rac-17f*) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).
- [13] D. A. Price, N. S. Simpkins, A. M. MacLeod, A. P. Watt, J. Org. Chem. 1994, 59, 1961.
- [14] a) T. Volk, D. Bernicke, J. W. Bats, H.-G. Schmalz, Eur. J. Inorg. Chem. 1998, 1883; b) J. Blagg, S. J. Coote, S. G. Davies, B. E. Mobbs, J. Chem. Soc. Perkin Trans. 1 1986, 2257.
- [15] D. J. Peterson, Organomet. Chem. Rev. Sect. A 1972, 7, 295.
- [16] A diastereomeric mixture of *rac-***13** and *rac-***11h** (7.5:1) was formed, which was easily separated by chromatography.
- [17] In this case, a by-product (19%) of type **10** was obtained which indicates a strong kinetic isotope effect (abstraction of D_{endo} at C1 versus H_{exo} at C3).
- [18] A participation of the ring oxygen atom (as a coordinating site) in the endo deprotonation step is likely, as other benzylic silylated [arene Cr(CO)₃] complexes do not exhibit such behavior; see, for example: J. Blagg, S. J. Coote, S. G. Davies, D. Middlemiss, A. Naylor, J. Chem. Soc. Perkin Trans. 1 1987, 689.
- [19] For other examples of *exo*-protonation of Cr(CO)₃-complexed benzylic anions, see refs. [10a, e], as well as: H.-G. Schmalz, S. Siegel, D. Bernicke, *Tetrahedron Lett.* 1998, 39, 6683.
- [20] The base 18 was prepared from R-(+)-1-phenylethylamine: see: N. S. Simpkins, K. Bambridge, M. J. Begley, *Tetrahedron Lett.* 1994, 35, 2301
- [21] The absolute configuration of 11a was determined by X-ray crystalstructure analysis^[12] and confirmed the expected results.^[11b]

Chemically Tuning between Ferromagnetism and Antiferromagnetism by Combining Theory and Synthesis in Iron/Manganese Rhodium Borides**

Richard Dronskowski,* Karol Korczak, Heiko Lueken, and Walter Jung

Dedicated to Professor Welf Bronger on the occasion of his 70th birthday

Cooperative magnetic phenomena such as ferromagnetism and antiferromagnetism have not only made up an enormously rich synthetic and theoretical playground for generations of solid-state physicists and chemists, [1, 2] they also form the material basis of the most critical key technology of today's information society, namely data storage and data retrieval.^[3, 4] Fortunately enough, within the last two decades modern high-level electronic-structure calculations of the density-functional type have proven to be able to reproduce a number of essential observables (e.g., magnetic moments) in many (inter)metallic magnets with satisfying accuracy, thereby offering a first step in an atomistic understanding of these magnetic properties. Only recently, however, has it been shown that a more chemically oriented theoretical framework, intended to offer semiquantitative signposts for the synthesis of new cooperative magnets, can be constructed simply by identifying bonding "fingerprints" which are characteristic for either metallic ferromagnets or antiferromagnets.[5, 6]

When a nonmagnetic ("spin-restricted") band-structure calculation is performed on a typical ferromagnet such as bcc-Fe, a crystal orbital Hamilton population (COHP) bonding analysis yields antibonding Fe-Fe interactions at the Fermi level (Figure 1, top left), which indicates an electronic instability. Upon spontaneous spin polarization ("spin-unrestricted" calculation), bcc-Fe undergoes a distortion, but instead of the atoms the electrons rearrange themselves.[7] Thus, spontaneous magnetization makes the spin-up (a) and spin-down (β) electrons inequivalent, thereby reducing the electronic symmetry, which annihilates the antibonding states and, consequently, lowering the overall energy and the bonding energy by a few percent (Figure 1, top right). [5, 6] For antiferromagnetism, things are a little bit more subtle. A corresponding nonmagnetic band-structure calculation on a typical antiferromagnet such as bcc-Cr results in the Fermi level being positioned exactly between the bonding and

^[*] Prof. Dr. R. Dronskowski, K. Korczak, Prof. Dr. H. Lueken Institut für Anorganische Chemie Rheinisch-Westfälische Technische Hochschule Professor-Pirlet-Strasse 1, 52056 Aachen (Germany) Fax: (+49)241-80-92288 E-mail: drons@HAL9000.ac.rwth-aachen.de Prof. Dr. W. Jung Institut für Anorganische Chemie der Universität zu Köln Greinstrasse 6, 50939 Köln (Germany)

^[**] It is a pleasure to thank Dipl.-Chem. Uwe Couhorn, Dipl.-Chem. Yasemin Kurtulus, and Dr. Bernhard Eck for assistance as well as the Fonds der Chemischen Industrie for their support.